Tiziana Life Sciences Ltd., a biotechnology company focused on developing innovative immunomodulation therapies, has announced that its CEO, Ivor Elrifi, will present recent clinical findings related to its lead drug candidate, intranasal foralumab, at the Bio International Convention in Boston, Massachusetts. The presentation, titled "Treatment of Neuroinflammation with Intranasal Foralumab," is scheduled for June 18, 2025, at 11:45 AM ET. Intranasal foralumab is the first fully human anti-CD3 monoclonal antibody administered via the intranasal route, aiming to promote immune tolerance with minimal systemic immune suppression. Tiziana Life Sciences is currently conducting a Phase 2 trial for non-active Secondary Progressive Multiple Sclerosis and is planning to initiate a Phase 2 trial for early Alzheimer's Disease. The results of these trials will be discussed during the presentation.